Holen Sie sich die Stockscreener-App
47.27
4.19%
1.90
Handel nachbörslich:
47.27
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Kiniksa Pharmaceuticals (KNSA) CMO sells 40K shares after option exercise - Stock Titan
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility - simplywall.st
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential With 23% Upside - DirectorsTalk Interviews
Kiniksa (NASDAQ: KNSA) Rule 144 notice: 40,000-share cashless exercise - Stock Titan
KNSA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing - ChartMill
KNSA/N Stock Price and Chart — BIVA:KNSA/N - TradingView
Pharma firm Kiniksa offers live March 2 TD Cowen health care chat - Stock Titan
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
KNSA: Wells Fargo Raises Price Target and Maintains Overweight R - GuruFocus
KNSA: Wedbush Raises Price Target to $53, Maintains Outperform R - GuruFocus
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment - ChartMill
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Biopharma's Strong Growth Trajectory And 17.9% Upside Potential - DirectorsTalk Interviews
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens - MSN
Beyond the Balance Sheet: What SWOT Reveals About Kiniksa Pharma - GuruFocus
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kiniksa Pharmaceuticals International, plcClass A Ordinary Shares (NQ: KNSA - The Chronicle-Journal
Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earning - GuruFocus
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 49.12 - Markets Mojo
Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharmaceuticals: A Multibagger with 140.68% Return and Strong Financial Metrics - Markets Mojo
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Down 6.3% on Feb 24 - GuruFocus
Kiniksa Pharmaceuticals International, plc 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KNSA) 2026-02-24 - Seeking Alpha
Wedbush Adjusts Kiniksa Pharmaceuticals International Price Target to $53 From $50, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down on Disappointing Earnings - MarketBeat
KNSA Reports Q4 Revenue, Expects Strong Future Growth - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates - Yahoo Finance
Kiniksa Pharmaceuticals International PLC reports results for the quarter ended December 31Earnings Summary - TradingView
KNSA: Arcalyst revenue up 62% to $677.6M in 2025, with strong outlook and expanding market reach - TradingView
Kiniksa Pharmaceuticals International : Corporate Presentation – February 2026 - marketscreener.com
Kiniksa Pharmaceuticals Swings to Q4 Net Income, Revenue Increases - marketscreener.com
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q4 EPS $0.17, vs. FactSet Est of $0.34 - marketscreener.com
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International, plc Reports Q4 Revenue $202.1M, vs. FactSet Est of $200.8M - marketscreener.com
ARCALYST drives Kiniksa (NASDAQ: KNSA) 62% 2025 revenue surge - Stock Titan
Kiniksa Pharmaceuticals Q4 Earnings Assessment - Benzinga
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa shifts from 2024 loss to $59M profit, builds cash - Stock Titan
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Do Options Traders Know Something About KNSA Stock We Don't? - TradingView
Kiniksa Pharmaceuticals Set to Announce Q4 Earnings - Intellectia AI
Kiniksa Pharmaceuticals International, plc Q4 2025 earnings preview - MSN
Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges - AOL.com
Kiniksa Pharmaceuticals International, plc Q3 2025 Earnings Preview - MSN
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Hillsdale Investment Management Inc. - MarketBeat
Aberdeen Group plc Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International PLC expected to post earnings of 37 cents a shareEarnings Preview - TradingView
Kiniksa Pharmaceuticals International, plc (KNSA) earnings expected to grow: Should you buy? - MSN
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - ChartMill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week HighHere's Why - MarketBeat
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 3.15% H - GuruFocus
KNSA: Canaccord Genuity Initiates Coverage with a Buy Rating | K - GuruFocus
Canaccord Genuity Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $62 Price Target - marketscreener.com
Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy? - Bitget
GSA Capital Partners LLP Has $3.03 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
0.21%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):